FOLH1 and prostate cancer: The LuTectomy trial (NCT04430192) is a phase I/II study evaluating 177Lu-PSMA-617 in patients with high-risk localized or locoregional advanced prostate cancer before radical prostatectomy and pelvic lymph node dissection, and demonstrated that two cycles of 177Lu-PSMA-617 prior to surgery were tolerated with minimal adverse effects [97].